Chiffres calculés à partir des déclarations réglementaires officielles — .
Analystesobjectif 20.52 USD (+128%) · consensus 5/5 · 5 achat · 0 conserver · 0 vente
Détentioninitiés 0.12% · institutions 1.02% · vente à découvert 0.1% du flottant
En USD · au Oct 26, 2026
Interroger la machine
Recherchez et comparez les opérations d’initiés, les sociétés et leurs statistiques en langage courant. Votre question devient une requête sur les données disponibles, pas une conversation ni un conseil en investissement.
Données de Telix Pharmaceuticals Ltd uniquement. Pas de recherche web. Les statistiques globales d’un initié sont exclues.
Une recherche exécutée consomme un crédit, même sans résultat. Les erreurs et les questions non prises en charge ne consomment rien.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Source des informations de marché · Oct 26, 2026
Identité selon la SEC · Oct 26, 2026
Chronologie sur le marché · historique complet
3 achats— cours de clôturebarre = volume usd, échelle √cliquez sur une période pour filtrer le tableau
| Initié | Type | Valeur · USD | Signaux | Détail |
|---|---|---|---|---|
| Smith Darren Charlton | Achat | $20K | conv 60Premier en 12 mois |
| SEC |
| Behrenbruch Christian | Achat | $499.6K | conv 44Premier en 12 mois | SEC |
| Behrenbruch Christian | Achat | $497.2K | conv 36 | SEC |
| Smith Darren Charlton | ExerciceD (dérivé) | n.d. (Transaction sans contrepartie en espèces : la déclaration indique un prix nul (attribution, don, exercice)) | SEC |
| Smith Darren Charlton | Exercice | n.d. (Transaction sans contrepartie en espèces : la déclaration indique un prix nul (attribution, don, exercice)) | SEC |